The bidding war goes on to acquire Obagi Medical Products (NASDAQ: OMPI) and its dermatological product line, with the acquisitive Valeant Pharmaceuticals (BHC 1.96%) as the current top bidder at $24 per share. The ongoing bidding war has Obagi up another 10% today. Are we close to seeing a deal? In this video, Fool health-care analyst David Williamson tells investors how to play this buyout bidding race, both for current shareholders, and for those currently sitting on the sidelines.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.